Amarin Corp plc (AMRN) Files $300M Mixed Securities Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal
August 8, 2014 1:05 PM EDTGoldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 results. Analyst Gary Nachman said he was awaiting FDA response on its ANCHOR appeal.
"The Vascepa co-promote with Kowa began in mid-May and we have started to see a positive impact on Rxs, but it is... More
Aegis Capital Comments on Amarin (AMRN) Following Q2 Results, Commercialization Update
August 8, 2014 9:23 AM EDTAegis Capital affirms its Buy rating and $2 price target on Amarin (Nasdaq: AMRN) following Q2 results.
Analyst Ram Selvaraju commented, [Amarin] recorded $12.6mm in Vascepa sales, below our estimate of $14mm. R&D expenses were $11.7mm, slightly above our forecast of $10mm, and SG&A expenses were $21.1mm, also above our projection of $18mm. While the firm reported earnings per share of $0.08 vs. our expectation of a... More
Amarin Corp plc (AMRN) Tops Q2 EPS by 1c
August 7, 2014 4:24 PM EDTAmarin Corp plc (NASDAQ: AMRN) reported Q2 EPS of ($0.14), $0.01 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $12.86 million.
Amarin reported cash and cash equivalents of $150.5 million at June 30, 2014, representing a net decrease of $13.8 million from reported cash and cash equivalents of $164.3 million as of March 31, 2014... More
